There are remarkable differences in the diagnostic and therapeutic management of atopic
dermatitis practiced by dermatologists and pediatricians in different countries. Therefore, the …

Currently, the most relevant data are those for cyclosporine, alitretinoin, and dupilumab.
Cyclosporine and dupilumab showed to be effective in the treatment of atopic dermatitis …

Background Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks
signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous …

Background Significant unmet need exists for long-term treatment of moderate to severe
atopic dermatitis (AD). Objective To assess the long-term safety and efficacy of dupilumab in …

Many systemically effective drugs such as cyclosporin A are ineffective topically because of
their poor penetration into skin. To surmount this problem, we conjugated a heptamer of …

Guidelines/Outcomes Task Force: Abby Van Voorhees, MD, Chair Task Force, Mark A.
Bechtel, MD, Boni E. Elewski, MD, Steven R. Feldman, MD, Cindy Francyn Hoffman, MD …

Background The skin of up to 100% of patients with atopic dermatitis (AD) is colonized with
Staphylococcus aureus. Of all S. aureus strains isolated from lesional skin, up to 65% have …

Objective To systematically assess the effectiveness of systemic cyclosporin in patients with
severe atopic eczema. Study design Systematic review and meta‐analysis of controlled and …

Cyclosporin (CyA) has been shown to be highly effective and well tolerated in the short‐term
treatment of severe childhood atopic dermatitis; however, there is limited experience in its …

Atopic dermatitis, one of the most common skin disorders in young children, has a
prevalence of 10% to 20% in the first decade of life. It is a chronic illness that requires a …